In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Trump's Sights Set On Payers And Pharmas, But Medtechs Must Not Be Complacent

Executive Summary

It's been a big month for plans intended to shape the future of health care in the US, with the Trump Administration showcasing its ACA replacement bill and issuing budget proposals. At this stage, it's hard to peg winners and losers and although the focus is squarely on insurance, the medtech sector should guard against complacency, says ZS Associates' Brian Chapman.

You may also be interested in...



GOP Action To Push Through ACA-Replace Bill Threatens Device Tax Repeal

Republican action to ram an Affordable Care Act replacement bill through two House committees overnight, without a Congressional Budget Office score and over the objections of powerful health-care interests, appears to be undermining support for the American Health Care Act, threatening ultimate congressional passage of the bill and its device-tax repeal provision.

US Medtech Under Trump: Below The Radar Or In The Line Of Fire?

The return of a Republican president to power in last month's US elections showed – for the second time in 2016 – that punditry can be misleading and opinion polls do not always equate with reality. With just a few weeks to President Trump's inauguration, ZS Associates' Brian Chapman gives an early appraisal of how the new administration might view the health care brief in general and the medtech industry in particular.

The Sustainability Stakes Are Rising: ‘We Cannot Recycle Our Way Out Of This’

The journey to Net Zero, described as ‘the defining issue of our time,’ will get harder in the coming decade. Failure to keep up the pressure will result in more long-term health conditions, increasing deaths and higher costs. The UK NHS is a Net Zero exemplar globally, but without a systemic approach, its compliance efforts could stutter.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

IV005057

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel